Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collabor...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: S. G. P. Funnell, W. E. Dowling, C. Muñoz-Fontela, P.-S. Gsell, D. E. Ingber, G. A. Hamilton, L. Delang, J. Rocha-Pereira, S. Kaptein, K. H. Dallmeier, J. Neyts, K. Rosenke, E. de Wit, H. Feldmann, P. Maisonnasse, R. Le Grand, M. B. Frieman, C. M. Coleman
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/16f0fbaa1ef74b81ae8f7a0d0a46c7fa
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.

Ejemplares similares